Increase transparency and reproducibility of real‐world evidence in rare diseases through disease‐specific Federated Data Networks

Abstract

AbstractPurposeIn rare diseases, real‐world evidence (RWE) generation is often restricted due to small patient numbers and global geographic distribution. A federated data network (FDN) approach brings together multiple data sources harmonized for collaboration to increase the power of observational research. In this paper, we review how to increase reproducibility and transparency of RWE studies in rare diseases through disease‐specific FDNs.MethodTo be successful, a multiple stakeholder scientific FDN collaboration requires a strong governance model in place. In such a model, each database owner remains in full control regarding the use of and access to patient‐level data and is responsible for data privacy, ethical, and legal compliance. Provided that all this is well documented and good database descriptions are in place, such a governance model results in increased transparency, while reproducibility is achieved through data curation and harmonization, and distributed analytical methods.ResultsLeveraging the OHDSI community set of methods and tools, two rare disease‐specific FDNs are discussed in more detail. For multiple myeloma, HONEUR—the Haematology Outcomes Network in Europe—has built a strong community among the data partners dedicated to scientific exchange and research. To advance scientific knowledge in pulmonary hypertension (PH) an FDN, called PHederation, was established to form a partnership of research institutions with PH databases coming from diverse origins.